HREC approves initiation of FIH Ph 1/2 Trial of ML-016 in Advanced Cancers with Lung and/or Liver Involvement October 15, 2025
Trogenix announces £70M/$95M Series A financing to drive clinical development of potentially curative therapies for aggressive cancers October 7, 2025
Cartography Secures $67 Million Series B Financing to Advance Differentiated Oncology Pipeline of Antibody-Based Therapies into the Clinic October 7, 2025
Initial clinical data for BDC-4182 Ph 1 dose escalation study now expected in 3Q 2026 October 7, 2025
Alignment with FDA obtained on study design to advance two Ph 3 trials in gastroesophageal cancers (FAPI-GO) and PDAC (FAPI-PRO), with [18F] FAPI-74 October 7, 2025
Encouraging Preliminary Results from the Pancreatic Cancer Cohort of Ph 1/2a CENDIFOX Trial of certepetide + chemo combo Announced September 30, 2025
Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned September 30, 2025
86% OS at 9 Months observed in 1L Pancreatic Cancer Patients Treated with Atebimetinib + mGnP September 30, 2025
FDA Granted Orphan Drug Designation to Utidelone for the Treatment of Pancreatic Cancer September 30, 2025
ELI-002 7P Achieved Robust mKRAS-Specific T Cell Responses in 99% of Evaluable pancreatic cancer patients in Ph 2 AMPLIFY-7P Trial September 23, 2025
IND application amended with updated OS data from Ph 2 Actuate-1801 Part 3B trial of elraglusib + GnP versus GnP alone in 1L metastatic pancreatic cancer September 23, 2025
Pidnarulex (CX-5461) + Cemiplimab (Libtayo®) combo to be tested in Ph 1/2 clinical trial for MSS CRC patients September 23, 2025
Adagene Expands SAFEbody® Collaboration and License Agreement with Exelixis to Develop Third Novel Masked ADC September 23, 2025
First Patient Dosed in Ph 2 Study of AK130 + Ivonescimab for Advanced Pancreatic Cancer September 23, 2025
Patients With Aggressive Brain and Advanced Liver Cancers Treated with PIC monotherapy Reach Five Years of Durable RFS September 23, 2025
Final results from OPTIMIZE-1 trial of mitazalimab – mFOLFIRINOX combo in 1L metastatic pancreatic cancer patients announced September 23, 2025
New Data Supports Initiation of Ph 3 RASolute 303 Registrational Trial of Daraxonrasib in 1L Metastatic Pancreatic Ductal Adenocarcinoma September 16, 2025
Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer September 16, 2025
Bayer and Kumquat Biosciences enter global exclusive license and collaboration in precision oncology September 16, 2025
First Patient Dosed in Global Registrational Trial of Cadonilimab for PD-1 Treatment-Resistant HCC September 16, 2025
NMPA accepts NDA for KN026 in patients with HER2+ve locally advanced, recurrent, or metastatic gastric or GEJ cancer September 16, 2025
Survival benefit for bemarituzumab + chemo in 1L gastric cancer attenuates at final analysis September 9, 2025
In KRAS mutant 2L mCRC, pelareorep delivers prolonged survival benefit with a median PFS and median OS approximately 2.5x the current SOC September 9, 2025
TREOS Bio, Charité Berlin, and Junshi Biosciences to Launch Pivotal Ph 2 Trial of PolyPEPI1018, toripalimab, and SoC combo in Refractory MSS CRC September 3, 2025
